KemPharm Q3 net loss $0.05/sh; appoints Richard Pascoe as Executive Chairman

ZEVRA THERAPEUTICS, INC.

2021-Q3 EPS reported -$2.16 revenue$26,068,000

Q3 2021 net loss $1.8M ($0.05 per basic share); revenue $2.0M (mostly service fees).
Cash and equivalents $131.5M at Sep 30, 2021; 35.3M shares outstanding basic.
Richard W. Pascoe appointed Executive Chairman, effective Nov 10, 2021.
Pascoe receives $400K base salary, option for 100K shares with performance vesting.
AZSTARYS commercial launch initiated Jul 21; >50M lives now have access per Corium.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard W. Pascoe

Executive Chairman

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2021-11-10
Filed: November 10, 2021, 6:59 PM ET

On November 5, 2021, the Board of Directors of KemPharm appointed Richard W. Pascoe as KemPharm’s Executive Chairman.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard W. Pascoe was appointed as Executive Chairman at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: Executive Chairman

Exact text from the filing

On November 5, 2021, the Board of Directors of KemPharm appointed Richard W. Pascoe as KemPharm’s Executive Chairman.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-21-026154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.